Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

666.14
+4.560.69%
Number of Gainers:76
Number of Losers:54
Number of Flat:23
PE:- -
High:667.23
Open:662.15
Low:662.15
Close:662.00
Volume:10.15M
Turnover:253.74M
Market Cap:461.59B
Float Cap:354.55B

Loading ...

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 02

Quince Therapeutics Announces Conditional Board Restructuring Plans

TIPRANKS
·
Oct 02

Wells Fargo Initiates Robinhood Markets at Equalweight

MT Newswires Live
·
Oct 02

On Semi, Synaptics, Nike, Strategy, Moderna, and More Stocks That Explain Today's Market

Dow Jones
·
Oct 02

Piper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Oct 02

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Oct 02

Coinbase price target raised to $170 from $146 at Piper Sandler

TIPRANKS
·
Oct 02

Phillips Edison Expands Joint Venture, Reaffirms 2026 Guidance

TIPRANKS
·
Oct 02

Analysts Conflicted on These Technology Names: Monday.com (MNDY), Nvidia (NVDA) and Synaptics (SYNA)

TIPRANKS
·
Oct 02

Stocks to Watch: Nike, SoftBank, Strategy

Dow Jones
·
Oct 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 02

Summit Therapeutics enters trial collaboration with AstraZeneca, Daiichi Sankyo

TIPRANKS
·
Oct 02

Crypto-Linked Shares Climb as Bitcoin Rises About 2%

Reuters
·
Oct 02

Robinhood says stock token volume is nearing SEC exemption caps

cryptonews
·
Oct 02

Barclays Remains a Sell on Coinbase Global (COIN)

TIPRANKS
·
Oct 02

TenNor Therapeutics Calls 2026 Extraordinary Meeting to Revamp Incentives and Governance

TIPRANKS
·
Oct 02

Phillips Edison Reaffirms 2026 Core FFO Guidance

MT Newswires Live
·
Oct 02

TOKYO BASE Posts Solid September Sales and Ramps Up Autumn-Winter Inventory

TIPRANKS
·
Oct 02

Southbound 2x Long Coinbase ETF Rises Over 2% as Coinbase Secures UAE Financial Services Regulatory Authority Approval

Stock News
·
Oct 02

Qyuns Therapeutics' Oturkibart Shows Sustained Efficacy in Phase III Trial

MT Newswires Live
·
Oct 02